Saskia J Bogers1, Maarten F Schim van der Loeff2,3, Udi Davidovich3, Anders Boyd3,4, Marc van der Valk2, Kees Brinkman5, Godelieve J de Bree2, Peter Reiss2,4,6,7, Jan E A M van Bergen8,9, Suzanne E Geerlings2. 1. Department of Internal Medicine, Division of Infectious Diseases, Amsterdam University Medical Centers, University of Amsterdam, room D3-226, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands. s.j.bogers@amsterdamumc.nl. 2. Department of Internal Medicine, Division of Infectious Diseases, Amsterdam University Medical Centers, University of Amsterdam, room D3-226, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands. 3. Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands. 4. HIV Monitoring Foundation, Amsterdam, the Netherlands. 5. Department of Internal Medicine, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands. 6. Amsterdam Institute for Global Health and Development, Amsterdam, the Netherlands. 7. Department of Global Health, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands. 8. Department of General Practice, Amsterdam University Medical Centers, location Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. 9. STI AIDS Netherlands, Amsterdam, the Netherlands.
Abstract
BACKGROUND: Late presentation remains a key barrier towards controlling the HIV epidemic. Indicator conditions (ICs) are those that are AIDS-defining, associated with a prevalence of undiagnosed HIV > 0.1%, or whose clinical management would be impeded if an HIV infection were undiagnosed. IC-guided HIV testing is an effective strategy in identifying undiagnosed HIV, but opportunities for earlier HIV diagnosis through IC-guided testing are being missed. We present a protocol for an interventional study to improve awareness of IC-guided testing and increase HIV testing in patients presenting with ICs in a hospital setting. METHODS: We designed a multicentre interventional study to be implemented at five hospitals in the region of Amsterdam, the Netherlands. Seven ICs were selected for which HIV test ratios (proportion of patients with an IC tested for HIV) will be measured: tuberculosis, cervical/vulvar cancer or high-grade cervical/vulvar dysplasia, malignant lymphoma, hepatitis B and C, and peripheral neuropathy. Prior to the intervention, a baseline assessment of HIV test ratios across ICs will be performed in eligible patients (IC diagnosed January 2015 through May 2020, ≥18 years, not known HIV positive) and an assessment of barriers and facilitators for HIV testing amongst relevant specialties will be conducted using qualitative (interviews) and quantitative methods (questionnaires). The intervention phase will consist of an educational intervention, including presentation of baseline results as competitive graphical audit and feedback combined with discussion on implementation and opportunities for improvement. The effect of the intervention will be assessed by comparing HIV test ratios of the pre-intervention and post-intervention periods. The primary endpoint is the HIV test ratio within ±3 months of IC diagnosis. Secondary endpoints are the HIV test ratio within ±6 months of diagnosis, ratio ever tested for HIV, HIV positivity percentage, proportion of late presenters and proportion with known HIV status prior to initiating treatment for their IC. DISCUSSION: This protocol presents a strategy aimed at increasing awareness of the benefits of IC-guided testing and increasing HIV testing in patients presenting with ICs in hospital settings to identify undiagnosed HIV in Amsterdam, the Netherlands. TRIAL REGISTRATION: Dutch trial registry: NL7521 . Registered 14 February 2019.
BACKGROUND: Late presentation remains a key barrier towards controlling the HIV epidemic. Indicator conditions (ICs) are those that are AIDS-defining, associated with a prevalence of undiagnosed HIV > 0.1%, or whose clinical management would be impeded if an HIV infection were undiagnosed. IC-guided HIV testing is an effective strategy in identifying undiagnosed HIV, but opportunities for earlier HIV diagnosis through IC-guided testing are being missed. We present a protocol for an interventional study to improve awareness of IC-guided testing and increase HIV testing in patients presenting with ICs in a hospital setting. METHODS: We designed a multicentre interventional study to be implemented at five hospitals in the region of Amsterdam, the Netherlands. Seven ICs were selected for which HIV test ratios (proportion of patients with an IC tested for HIV) will be measured: tuberculosis, cervical/vulvar cancer or high-grade cervical/vulvar dysplasia, malignant lymphoma, hepatitis B and C, and peripheral neuropathy. Prior to the intervention, a baseline assessment of HIV test ratios across ICs will be performed in eligible patients (IC diagnosed January 2015 through May 2020, ≥18 years, not known HIV positive) and an assessment of barriers and facilitators for HIV testing amongst relevant specialties will be conducted using qualitative (interviews) and quantitative methods (questionnaires). The intervention phase will consist of an educational intervention, including presentation of baseline results as competitive graphical audit and feedback combined with discussion on implementation and opportunities for improvement. The effect of the intervention will be assessed by comparing HIV test ratios of the pre-intervention and post-intervention periods. The primary endpoint is the HIV test ratio within ±3 months of IC diagnosis. Secondary endpoints are the HIV test ratio within ±6 months of diagnosis, ratio ever tested for HIV, HIV positivity percentage, proportion of late presenters and proportion with known HIV status prior to initiating treatment for their IC. DISCUSSION: This protocol presents a strategy aimed at increasing awareness of the benefits of IC-guided testing and increasing HIV testing in patients presenting with ICs in hospital settings to identify undiagnosed HIV in Amsterdam, the Netherlands. TRIAL REGISTRATION: Dutch trial registry: NL7521 . Registered 14 February 2019.
Authors: Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Sanjay Mehendale; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Lei Wang; Joseph Makhema; Lisa A Mills; Guy de Bruyn; Ian Sanne; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Heather Ribaudo; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Thomas R Fleming Journal: N Engl J Med Date: 2011-07-18 Impact factor: 91.245
Authors: Caroline A Sabin; Colette J Smith; Helen Gumley; Gabrielle Murphy; Fiona C Lampe; Andrew N Phillips; Beth Prinz; Mike Youle; Margaret A Johnson Journal: AIDS Date: 2004-11-05 Impact factor: 4.177
Authors: Ann K Sullivan; Dorthe Raben; Joanne Reekie; Michael Rayment; Amanda Mocroft; Stefan Esser; Agathe Leon; Josip Begovac; Kees Brinkman; Robert Zangerle; Anna Grzeszczuk; Anna Vassilenko; Vesna Hadziosmanovic; Maksym Krasnov; Anders Sönnerborg; Nathan Clumeck; José Gatell; Brian Gazzard; Antonella d'Arminio Monforte; Jürgen Rockstroh; Jens D Lundgren Journal: PLoS One Date: 2013-01-15 Impact factor: 3.240
Authors: D Raben; A Mocroft; M Rayment; V M Mitsura; V Hadziosmanovic; Z M Sthoeger; A Palfreeman; S Morris; G Kutsyna; A Vassilenko; J Minton; C Necsoi; V P Estrada; A Grzeszczuk; V Svedhem Johansson; J Begovac; E L C Ong; A Cabié; F Ajana; B M Celesia; F Maltez; M Kitchen; L Comi; U B Dragsted; N Clumeck; J Gatell; B Gazzard; A d'Arminio Monforte; J Rockstroh; Y Yazdanpanah; K Champenois; M L Jakobsen; A Sullivan; J D Lundgren Journal: PLoS One Date: 2015-11-11 Impact factor: 3.240
Authors: Saskia J Bogers; Maarten F Schim van der Loeff; Anders Boyd; Udi Davidovich; Marc van der Valk; Kees Brinkman; Kim Sigaloff; Judith Branger; Nejma Bokhizzou; Godelieve J de Bree; Peter Reiss; Jan E A M van Bergen; Suzanne E Geerlings Journal: Lancet Reg Health Eur Date: 2022-10-07